Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPoolbeg Pharma Regulatory News (POLB)

Share Price Information for Poolbeg Pharma (POLB)

Share Price is delayed by 15 minutes
Get Live Data
8.50    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 0.50 (6.25%)
Market Cap: £59.93m
POLB Live PriceLast checked at - London Stock Exchange

Intraday Poolbeg Pharma Share Chart

Form 8.5 (EPT/RI) - Poolbeg Pharma Plc

8 Jan 2025 10:51

Form 8.5 (EPT/RI) - Poolbeg Pharma Plc

FORM 8.5 (EPT/RI)

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the β€œCode”)

1. KEY INFORMATION

(a) Name of exempt principal trader:Shore Capital Stockbrokers Ltd
(b) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offereePoolbeg Pharma Plc
(c) Name of the party to the offer with which exempt principal trader is connected:Poolbeg Pharma Plc
(d) Date dealing undertaken:07 January 2025
(e) Has the EPT previously disclosed, or is it today disclosing, under the Code in respect of any other party to this offer?No

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

(a) Purchases and sales

Class of relevant securityPurchases/ sales Total number of securitiesHighest price per unit paid/receivedLowest price per unit paid/received
OrdinaryPurchases687,3294.44p3.8425p
OrdinarySales757,2564.5625p4.08p

(b) Derivatives transactions (other than option)

Class of relevant securityProduct description e.g. CFDNature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short positionNumber of reference securitiesPrice per unit
Β Β Β Β Β 

(c) Options transactions in respect of existing securities

(i) Writing, selling, purchasing or varying

Class of relevant securityProduct description e.g. call optionWriting, purchasing, selling, varying etc.Number of securities to which option relatesExercise price per unitType e.g. American, European etc.Expiry dateOption money paid/ received per unit
Β Β Β Β Β Β Β Β 

(ii) Exercising

Class of relevant securityProduct description e.g. call optionNumber of securitiesExercise price per unit
Β Β Β Β 

(d) Other dealings (including subscribing for new securities)

Class of relevant securityNature of dealing e.g. subscription, conversionDetailsPrice per unit (if applicable)
Β Β Β Β 

The currency of all prices and other monetary amounts should be stated.

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

3. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer: If there are no such agreements, arrangements or understandings, state β€œnone”
None

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state β€œnone”
None

Date of disclosure:08 January 2025
Contact name:Laura Parmenter
Telephone number:0207 647 8154

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s dealing disclosure requirements on +44 (0)20 7638 0129. The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

Date   Source Headline
11th May 20232:27 pmRNSResults of Annual General Meeting
12th Apr 20237:00 amRNSAnnual Report & AGM Notice
30th Mar 20237:00 amRNSResults for the year ended 31 December 2022
10th Mar 20237:00 amRNSNotification of Major Holdings
9th Mar 20233:51 pmRNSNotification of Major Holdings
8th Mar 20237:00 amRNSPOLB 001 patent portfolio strengthened
2nd Mar 202311:05 amRNSSecond Price Monitoring Extn
2nd Mar 202311:00 amRNSPrice Monitoring Extension
2nd Mar 20237:00 amRNSPositive Results POLB001 LPS Human Challenge Trial
16th Jan 20237:00 amRNSStrategic expansion of POLB 001 into oncology
9th Jan 20239:05 amRNSSecond Price Monitoring Extn
9th Jan 20239:00 amRNSPrice Monitoring Extension
9th Jan 20237:00 amRNSPositive Initial Data Analysis in POLB 001 Trial
22nd Dec 202210:48 amEQSPoolbeg Pharma identifies new RSV drug candidates
21st Dec 20227:00 amRNSPoolbeg identifies novel RSV drug candidates
15th Dec 20229:49 amEQSPoolbeg Pharma makes 'interesting addition to existing collaboration'
14th Dec 20227:00 amRNSMetabolic diseases oral delivery licence signed
12th Dec 20222:05 pmRNSSecond Price Monitoring Extn
12th Dec 20222:00 pmRNSPrice Monitoring Extension
12th Dec 202212:00 pmEQSPoolbeg Pharma receives initial results from human challenge clinical study
12th Dec 20227:00 amRNSPOLB 001 LPS human challenge trial completed
29th Nov 20227:00 amRNSInfluenza AI model build completed
21st Nov 202211:37 amEQSPoolbeg Pharma wins first non-dilutive grant funding
18th Nov 20222:00 pmRNSPrice Monitoring Extension
17th Nov 20222:05 pmRNSSecond Price Monitoring Extn
17th Nov 20222:00 pmRNSPrice Monitoring Extension
17th Nov 20227:00 amRNSCapital Markets Day
15th Nov 202210:36 amRNSPoolbeg-led consortium awarded EUR 2.3m grant
9th Nov 20221:53 pmEQSPoolbeg Pharma makes virus 'breakthrough' using AI drug discovery technology
8th Nov 20227:00 amRNSAI programme yields novel RSV drug targets
21st Oct 20227:00 amRNSUpcoming events participation
6th Oct 20224:40 pmRNSSecond Price Monitoring Extn
6th Oct 20224:35 pmRNSPrice Monitoring Extension
6th Oct 20227:00 amRNSCEO Share Purchase
4th Oct 20227:00 amRNSPOLB 001 US Patent update
21st Sep 20227:00 amRNSPoolbeg licence of Melioidosis vaccine candidate
12th Sep 20227:00 amRNSHC Wainwright Global Investment Conference
6th Sep 20222:05 pmRNSSecond Price Monitoring Extn
6th Sep 20222:00 pmRNSPrice Monitoring Extension
6th Sep 20227:00 amRNSInterim Results
31st Aug 20227:25 amRNSNotice of Results
29th Jul 20227:00 amRNSAppointment of Joint Broker
20th Jul 20227:00 amRNSPOLB001 human challenge clinical trial to commence
12th Jul 20222:06 pmRNSSecond Price Monitoring Extn
12th Jul 20222:00 pmRNSPrice Monitoring Extension
27th Jun 20227:00 amRNSProject update for AI model of RSV data
21st Jun 20224:40 pmRNSSecond Price Monitoring Extn
21st Jun 20224:36 pmRNSPrice Monitoring Extension
26th May 20222:05 pmRNSSecond Price Monitoring Extn
26th May 20222:00 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.